MA50403A - Promédicaments de dantrolène et leurs procédés d'utilisation - Google Patents

Promédicaments de dantrolène et leurs procédés d'utilisation

Info

Publication number
MA50403A
MA50403A MA050403A MA50403A MA50403A MA 50403 A MA50403 A MA 50403A MA 050403 A MA050403 A MA 050403A MA 50403 A MA50403 A MA 50403A MA 50403 A MA50403 A MA 50403A
Authority
MA
Morocco
Prior art keywords
dantrolene
medicinal products
use procedures
procedures
medicinal
Prior art date
Application number
MA050403A
Other languages
English (en)
Inventor
Adrian Hepner
Alyssa Larson
Charles Wescott
Original Assignee
Eagle Res Labs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eagle Res Labs Limited filed Critical Eagle Res Labs Limited
Publication of MA50403A publication Critical patent/MA50403A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
MA050403A 2017-10-20 2018-10-19 Promédicaments de dantrolène et leurs procédés d'utilisation MA50403A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762575124P 2017-10-20 2017-10-20
US201862674422P 2018-05-21 2018-05-21

Publications (1)

Publication Number Publication Date
MA50403A true MA50403A (fr) 2021-04-28

Family

ID=64277793

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050403A MA50403A (fr) 2017-10-20 2018-10-19 Promédicaments de dantrolène et leurs procédés d'utilisation

Country Status (19)

Country Link
US (3) US11352347B2 (fr)
EP (2) EP3697779B1 (fr)
JP (2) JP7252963B2 (fr)
KR (1) KR102652642B1 (fr)
CN (1) CN111344286A (fr)
AU (2) AU2018351494C1 (fr)
BR (1) BR112020007858A2 (fr)
CA (1) CA3079558A1 (fr)
CO (1) CO2020006193A2 (fr)
ES (1) ES3016835T3 (fr)
IL (1) IL274045B2 (fr)
MA (1) MA50403A (fr)
MX (2) MX2020003400A (fr)
MY (1) MY201417A (fr)
NZ (1) NZ763377A (fr)
SG (1) SG11202003452XA (fr)
UA (1) UA127738C2 (fr)
WO (1) WO2019079721A1 (fr)
ZA (1) ZA202002779B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11352347B2 (en) * 2017-10-20 2022-06-07 Eagle Research Labs Limited Dantrolene prodrugs and methods of their use
KR20210096152A (ko) * 2018-11-27 2021-08-04 이글 리서치 랩스 리미티드 방사선 노출을 치료하기 위한 단트롤렌 및 단트롤렌 전구약물의 용도
EP3771711A1 (fr) 2019-07-29 2021-02-03 Bayer Animal Health GmbH Dérivés de pyrazole pour le contrôle des arthropodes
AU2021254415A1 (en) 2020-04-10 2022-10-20 Cosette Pharmaceuticals, Inc. Methods of treating Severe Acute Respiratory Syndrome
WO2021207446A1 (fr) 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Méthodes de traitement d'infections virales
KR20230002371A (ko) 2020-04-10 2023-01-05 이글 파마슈티컬즈 인코포레이티드 SARS-CoV-2 감염증 치료 방법
WO2021207445A1 (fr) 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Méthodes de traitement d'infections à coronavirus

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3415821A (en) 1965-09-07 1968-12-10 Norwich Pharma Co 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones
US4137402A (en) 1978-03-30 1979-01-30 Morton-Norwich Products, Inc. Quaternary ammonium salts of dantrolene and clodanolene
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2674610C (fr) 2007-01-11 2013-06-18 Xenoport, Inc. Formes galeniques orales a liberation prolongee d'un promedicament de r-baclofene et procedes de traitement
EP2583670A1 (fr) 2007-10-09 2013-04-24 US Worldmeds LLC Compositions de co-solvants et procédés servant à améliorer la fourniture d'agents thérapeutiques à base de dantrolène
WO2009067175A2 (fr) 2007-11-16 2009-05-28 Nektar Therapeutics Al, Corporation Conjugués oligomère-dantrolène et composés associés
US20090306163A1 (en) 2008-06-10 2009-12-10 Pamela Renee Lipkin Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling
FR2944525B1 (fr) 2009-04-17 2011-06-24 Ipsen Pharma Sas Derives d'imidazolidine-2,4-dione et leur utilisation comme medicament
EP2765860B1 (fr) 2011-10-13 2016-08-17 Merck Sharp & Dohme Corp. Antagonistes d'un récepteur des minéralocorticoïdes
US9102645B2 (en) 2013-03-15 2015-08-11 Rosalind Franklin University Of Medicine And Science Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
US9725429B2 (en) 2013-03-15 2017-08-08 Rosalind Franklin University Of Medicine And Science Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release
EP2994134B1 (fr) 2013-05-06 2021-06-23 University Health Network Méthodes d'administration de dantrolène dans le traitement d'urgence des arythmies cardiaques
EP2994133A4 (fr) 2013-05-08 2016-11-16 Univ Howard Compositions et méthode de traitement des lésions neuronales de reperfusion ischémique
HUP1300720A2 (hu) 2013-12-12 2015-06-29 Univ Szegedi Gyógyászati készítmények sebgyógyulás elõsegítésére
WO2015182625A1 (fr) 2014-05-26 2015-12-03 国立大学法人京都大学 INHIBITEUR DE L'ACTIVITÉ Ras ET SON UTILISATION
US10441574B2 (en) 2014-11-13 2019-10-15 Washington University Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders
US11844782B2 (en) 2015-10-20 2023-12-19 Spepharm Ag Aqueous composition comprising dantrolene
US11352347B2 (en) * 2017-10-20 2022-06-07 Eagle Research Labs Limited Dantrolene prodrugs and methods of their use
SE542780C2 (en) 2018-09-15 2020-07-07 Coloreel Group AB A system and method for in-line treatment of thread

Also Published As

Publication number Publication date
EP4574832A3 (fr) 2025-09-17
JP2021500405A (ja) 2021-01-07
MY201417A (en) 2024-02-21
UA127738C2 (uk) 2023-12-20
SG11202003452XA (en) 2020-05-28
US20250145593A1 (en) 2025-05-08
IL274045B2 (en) 2023-09-01
IL274045A (en) 2020-06-30
EP3697779B1 (fr) 2025-03-05
EP4574832A2 (fr) 2025-06-25
NZ763377A (en) 2026-03-27
JP7252963B2 (ja) 2023-04-05
MX2020003400A (es) 2020-09-18
WO2019079721A1 (fr) 2019-04-25
AU2023278113B2 (en) 2025-09-04
AU2023278113A1 (en) 2024-01-04
ZA202002779B (en) 2023-10-25
KR102652642B1 (ko) 2024-04-01
US20200239455A1 (en) 2020-07-30
US12269815B2 (en) 2025-04-08
MX2023010501A (es) 2023-09-20
CN111344286A (zh) 2020-06-26
CA3079558A1 (fr) 2019-04-25
US11352347B2 (en) 2022-06-07
CO2020006193A2 (es) 2020-08-21
AU2018351494A1 (en) 2020-04-30
EP3697779A1 (fr) 2020-08-26
US20220324850A1 (en) 2022-10-13
RU2020116367A3 (fr) 2021-11-26
KR20200072514A (ko) 2020-06-22
IL274045B1 (en) 2023-05-01
JP2023061949A (ja) 2023-05-02
BR112020007858A2 (pt) 2020-10-27
ES3016835T3 (en) 2025-05-09
RU2020116367A (ru) 2021-11-22
AU2018351494C1 (en) 2025-10-23
AU2018351494B2 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
EP3678681A4 (fr) Variants de l'interleukine-18 et leurs procédés d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
EP3684423A4 (fr) Virus adéno-associé à variant de capsides et leurs procédés d'utilisation
MA50077A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA48772A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
EP3630199A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630788A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3630789A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3436048A4 (fr) Néoantigènes et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
EP3710430A4 (fr) Inhibiteurs d'acss2 et leurs procédés d'utilisation
MA48709A (fr) Conjugués de médicament à base de silicium et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
EP3684821A4 (fr) Anticorps anti-hla-a2 et leurs procédés d'utilisation
EP3307762A4 (fr) Variants de cas9 rapporteurs et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3436061A4 (fr) Compositions de conjugués saccharide-polypeptide polymérisables et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation